Characteristics of Sleep Patterns in Young Adults With and Without Insomnia

PHASE4CompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

February 28, 2002

Primary Completion Date

May 31, 2008

Study Completion Date

May 31, 2008

Conditions
Sleep Disorders
Interventions
DRUG

Zolpidem

The benzodiazepine receptor agonist (BzRA), zolpidem was given in an initial dose of 5 mg by mouth every night, 30 minutes prior to bedtime. The dose was increased to a maximum of 10 mg after the first week if there was no improvement in overall symptoms (CGI score of 4 or \>). The dose was decreased to 5 mg if side effects occurred.

DRUG

Escitalopram

The antidepressant, escitalopram was initiated at 5 mg by mouth every night, 30 minutes prior to bedtime. If there were no side effects, the dose was increased every four days until the target dose of 20 mg (maximum dose) was reached by day 13. If significant side effects appeared, the highest tolerated dose was used.

DRUG

Placebo

A placebo capsule was given with instructions to take it every night by mouth, 30 minutes prior to bedtime.

Trial Locations (1)

15213

Western Psychiatric Institute and Clinic/ University of Pittsburgh Medical Center, Pittsburgh

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

University of Pittsburgh

OTHER

NCT00177216 - Characteristics of Sleep Patterns in Young Adults With and Without Insomnia | Biotech Hunter | Biotech Hunter